reSET-O

Three reSET app screen examples
By  Dave Muoio 12:14 pm December 8, 2020
Prescription digital therapeutics startup Pear Therapeutics announced an $80 million Series D round this morning headed by SoftBank Vision Fund 2. The raise included funds from new backers Forth Management, Pilot House, Sarissa Capital, Shanda Group and QUAD Investment Management, as well as from returning investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis,...
By  Dave Muoio 01:55 pm November 5, 2020
A recently published review of real-world claims data suggests that opioid use disorder patients prescribed Pear Therapeutics' reSET-O digital therapeutic, alongside pharmacotherapy, had fewer clinical encounters and subsequently decreased medical costs over a six-month period. The study was funded by Pear, coauthored by a Pear employee and published in the journal Expert Review of...
By  Laura Lovett 03:23 pm June 24, 2020
Digital therapeutics company Pear Therapeutics has inked a deal with pharmacy benefits manager (PBM) RemedyOne, allowing the latter to offer and administer benefit coverage for the formers’ prescription-addiction-focused therapies reSET and reSET-O to its customers.  Both reSET and reSET-O have FDA clearances. In fact, reSET was the first software-only therapeutic to get the designation. reSET ...
By  Dave Muoio 01:57 pm January 9, 2020
Digital chronic care management company Livongo and health kiosk startup Higi have teamed up for a new program that will bring a Livongo-branded on-stage program to nearly 500 retail pharmacies in Michigan, the companies announced today. Through these and other channels, consumers will be able to measure indicators of chronic disease, enroll in Livongo programs, participate in health surveys and...
By  Dave Muoio 10:28 am October 16, 2019
Editor's Note: This story has been updated with additional quotes from Pear Therapeutics. The poster child of digital therapeutics-pharma collaborations is soon to be no more, as Novartis division Sandoz announced that it is handing sole responsibility for the commercialization of the reSET and reSET-O prescription digital therapeutics back to Pear Therapeutics. “Pear and Sandoz previously signed...
By  MobiHealthNews 11:25 am December 26, 2018
The pharma industry has become increasingly interested in the digital health space over the last few years, but this quarter numerous projects that have been in the works for years have finally came to fruition. For instance, Pear's reSET, the first digital therapeutic cleared by the FDA, was recently launched to commercial markets.  But that wasn’t the only advance in the space as pharma...
By  Laura Lovett 05:37 pm December 10, 2018
The FDA has officially cleared reSET-O — a digital therapeutic to treat opioid use disorder (OUD) jointly developed by Pear Therapeutics and Sandoz, a division of Novartis — a little over a year after it was granted an Expedited Access Pathway designation from the agency.  This announcement makes reSET-O the first digital therapeutic to treat patients with OUD. Patients will need a valid...